TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32916310

Group type: EXPERIMENTAL
Intervention: Almonertinib (HS-10296) at doses of 55, 110, 220 mg
Number of subjects: 120
Study: 32916704

Group type: EXPERIMENTAL
Intervention: Liver-directed gene therapy
Number of subjects: 8

Group type: COMPARATOR
Intervention: Phenobarbital-induced attacks
Number of subjects: 8

Group type: COMPARATOR
Intervention: AIP patients
Number of subjects: 8
Study: 32917138

Group type: EXPERIMENTAL
Intervention: Work Stress Questionnaire combined with feedback at consultation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ordinary consultative way of working
Number of subjects: 23
Study: 32917168

Group type: EXPERIMENTAL
Intervention: Histologic endometrial dating on day PO + 7 for RIF patients
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Conventional frozen-thawed embryo transfer (FET) after endometrial biopsy
Number of subjects: 205
Study: 32917192

Group type: EXPERIMENTAL
Intervention: 6% hydrogen peroxide gel
Number of subjects: 25

Group type: COMPARATOR
Intervention: 37.5% hydrogen peroxide gel
Number of subjects: 25
Study: 32917289

Group type: EXPERIMENTAL
Intervention: Cesarean section delivery
Number of subjects: 31

Group type: COMPARATOR
Intervention: No environmental risk factors
Number of subjects: 31
Study: 32917344

Group type: COMPARATOR
Intervention: Progression of valvular calcification (VC) at 1 site (AVC or MAC)
Number of subjects: 5591

Group type: COMPARATOR
Intervention: Progression of valvular calcification (VC) at 2 sites (AVC and MAC)
Number of subjects: 5591

Group type: COMPARATOR
Intervention: Progression of aortic valve calcification (AVC)
Number of subjects: 5591

Group type: COMPARATOR
Intervention: Progression of mitral annular calcification (MAC)
Number of subjects: 5591

Group type: EXPERIMENTAL
Intervention: Progression of valvular calcification (VC)
Number of subjects: 5591
Study: 32917355

Group type: EXPERIMENTAL
Intervention: Obese individuals with modified Mallampati classification of 4
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 29
Study: 32917537

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (DS-8201a)
Number of subjects: 0
Study: 32917626

Group type: EXPERIMENTAL
Intervention: Elevated serum ACE
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Lymphopaenia
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Combination of elevated serum ACE and lymphopaenia
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Combination of elevated serum ACE and lymphopaenia in patients aged ≤50 years
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Combination of elevated serum ACE and lymphopaenia in granulomatous uveitis
Number of subjects: 996
Study: 32917807

Group type: EXPERIMENTAL
Intervention: Traditionally defined status epilepticus (TSE)
Number of subjects: 2197

Group type: EXPERIMENTAL
Intervention: Operationally defined status epilepticus (OSE)
Number of subjects: 2197
Study: 32918045

Group type: EXPERIMENTAL
Intervention: SAF-189s, a new-generation ROS1/ALK inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crizotinib (first-generation ROS1 inhibitor)
Number of subjects: 0
Study: 32918305

Group type: EXPERIMENTAL
Intervention: Cluster 1 (Left ventricular disease)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Cluster 2 (Patent foramen ovale)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Cluster 3 (Arterial disease)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Cluster 4 (Atrial cardiopathy)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 800
Study: 32919178

Group type: EXPERIMENTAL
Intervention: apixaban 10 mg bid for seven days, then 5 mg bid for six months
Number of subjects: 298
Study: 32919398

Group type: EXPERIMENTAL
Intervention: Neuromelanin-sensitive MRI (NM-MRI)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: L-DOPA treatment for 3 weeks
Number of subjects: 33
Study: 32919458

Group type: EXPERIMENTAL
Intervention: Inappropriate initial antimicrobial regimens in clinical failure (CF) group
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Clinical failure (CF)
Number of subjects: 3011

Group type: COMPARATOR
Intervention: Clinical success (CS)
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: CF patients
Number of subjects: 3011

Group type: EXPERIMENTAL
Intervention: Discordant therapy
Number of subjects: 3011
Study: 32919461

Group type: EXPERIMENTAL
Intervention: Single Coma-Recovery Scale-Revised (CRS-R) assessment
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Repeated Coma-Recovery Scale-Revised (CRS-R) assessments (≥5 times within a week)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Clinical consensus diagnosis of EMCS
Number of subjects: 137
Study: 32919527

Group type: EXPERIMENTAL
Intervention: Intramuscular extended-dose fulvestrant 500 mg (Cohort A)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Oral neratinib 240 mg and intramuscular standard-dose fulvestrant (Cohort B)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Oral capivasertib 400 mg plus intramuscular standard-dose fulvestrant (Cohort C)
Number of subjects: 1034

Group type: EXPERIMENTAL
Intervention: Oral capivasertib 480 mg (Cohort D)
Number of subjects: 1034
Study: 32919861

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy non-obese women (control)
Number of subjects: 23
Study: 32920226

Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol, αT) 200-800 IU/d for 24 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vitamin E (α-tocopherol, αT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Redox-silenced methoxy-αT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxidative stress (OS)
Number of subjects: 20
Study: 32920453

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS) after PAP therapy
Number of subjects: 134

Group type: COMPARATOR
Intervention: Maintenance of Wakefulness Test (MWT)
Number of subjects: 134
Study: 32920652

Group type: EXPERIMENTAL
Intervention: Residual drug level (RDL) feedback from counselors
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Counselor communication strategies
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Personalized feedback on adherence measures
Number of subjects: 42
Study: 32920723

Group type: EXPERIMENTAL
Intervention: NOMAT model
Number of subjects: 287
Study: 32921507

Group type: EXPERIMENTAL
Intervention: Pentacel vaccine (Group 1)
Number of subjects: 1195

Group type: COMPARATOR
Intervention: Other brand of vaccine (Group 2)
Number of subjects: 1195

Group type: EXPERIMENTAL
Intervention: Delayed vaccinations
Number of subjects: 1195
Study: 32921790

Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 127

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 127
Study: 32922454

Group type: EXPERIMENTAL
Intervention: Electronic monitoring combined with IMS-based weekly feedback and reminders
Number of subjects: 96

Group type: COMPARATOR
Intervention: Electronic monitoring only (control group)
Number of subjects: 96
Study: 32922577

Group type: EXPERIMENTAL
Intervention: 30-min massage intervention
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reading control
Number of subjects: 12
Study: 32922827

Group type: EXPERIMENTAL
Intervention: Renal denervation (treatment group)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 10
Study: 32923144

Group type: EXPERIMENTAL
Intervention: Cytotoxic chemotherapy
Number of subjects: 294
Study: 32923151

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) + Azithromycin (AZI)
Number of subjects: 0
Study: 32923156

Group type: EXPERIMENTAL
Intervention: TIL therapy alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TIL combined with autologous tumor lysate-loaded DC vaccination
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/fludarabine preconditioning and intravenous IL-2 after TIL transfer
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DC vaccine (five intradermal injections)
Number of subjects: 10
Study: 32923446

Group type: EXPERIMENTAL
Intervention: Medical Qigong
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32923686

Group type: EXPERIMENTAL
Intervention: Foot thermometry with mHealth-based supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foot thermometry with mHealth-based supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32923849

Group type: EXPERIMENTAL
Intervention: Next-generation sequencing
Number of subjects: 517
Study: 32923850

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisolone (AAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32923853

Group type: EXPERIMENTAL
Intervention: Systematic genomic characterization
Number of subjects: 1045
Study: 32923921

Group type: EXPERIMENTAL
Intervention: LA-rich vegetable oil (10 mL/d)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oleic acid-rich oil (OA-oil)
Number of subjects: 18
Study: 32924093

Group type: EXPERIMENTAL
Intervention: SM-88 (230 mg BID), methoxsalen (10 mg), phenytoin (50 mg), sirolimus (0.5 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: SM-88
Number of subjects: 21
Study: 32924568

Group type: EXPERIMENTAL
Intervention: Fast-Acting Insulin Aspart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32924725

Group type: EXPERIMENTAL
Intervention: Diagnostic interviews
Number of subjects: 0
Study: 32924952

Group type: EXPERIMENTAL
Intervention: Peer navigation and text messaging interventions to support PrEP persistence and adherence.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Text messaging intervention with three messages per day.
Number of subjects: 0
Study: 32924986

Group type: EXPERIMENTAL
Intervention: ADXBLADDER test for MCM5 expression
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 119
Study: 32925091

Group type: EXPERIMENTAL
Intervention: Model 3B (muscles innervated by lower lumbar and sacral segments)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Strength assessed using Medical Research Council (MRC) score
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Distance walked on the 6-minute walk test (6MWT)
Number of subjects: 23
Study: 32925319

Group type: EXPERIMENTAL
Intervention: STOP-Bang scores of 5-8
Number of subjects: 115

Group type: COMPARATOR
Intervention: STOP-Bang scores of 3-4
Number of subjects: 115

Group type: COMPARATOR
Intervention: Alternative scoring models for STOP-Bang scores of 3-4
Number of subjects: 115
Study: 32925318

Group type: EXPERIMENTAL
Intervention: Continuous capnography and oximetry monitoring
Number of subjects: 1335

Group type: EXPERIMENTAL
Intervention: PRODIGY risk prediction model
Number of subjects: 1335
Study: 32925337

Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 32925387

Group type: EXPERIMENTAL
Intervention: TAF
Number of subjects: 106
Study: 32925554

Group type: EXPERIMENTAL
Intervention: Multiparametric MRI (mpMRI) measuring iron-corrected T1 (cT1)
Number of subjects: 81
Study: 32925563

Group type: EXPERIMENTAL
Intervention: Autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) injected intradermally at doses of 5, 15, and 50×10 cells/administration, every 2 weeks for 3 doses.
Number of subjects: 15
Study: 32925728

Group type: EXPERIMENTAL
Intervention: 12-week low FODMAP dietary intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy age- and gender-matched controls
Number of subjects: 100
Study: 32926343

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-obstructive sleep apnea patients
Number of subjects: 60
Study: 32926395

Group type: EXPERIMENTAL
Intervention: MTX treatment
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Prediction model (simplified by excluding SNPs)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Prediction model with interaction terms (BMI and HAQ, BMI and erythrocyte folate)
Number of subjects: 91
Study: 32926420

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (BV), median of four cycles (range one-16)
Number of subjects: 35
Study: 32926419

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 7944
Study: 32926574

Group type: EXPERIMENTAL
Intervention: RNA-seq for detection of SNVs/indels
Number of subjects: 3217

Group type: EXPERIMENTAL
Intervention: RNA-seq for mutation calling in genes such as PIK3CA, TP53, and ERBB2
Number of subjects: 3217

Group type: EXPERIMENTAL
Intervention: RNA-seq as a clinical tool
Number of subjects: 3217
Study: 32926761

Group type: EXPERIMENTAL
Intervention: Free PSA ratio (FPSAR) ≥0.10 in RP cohort
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Free PSA ratio (FPSAR) ≥0.10 in RT cohort
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Free PSA ratio (FPSAR) <0.10 in RP cohort
Number of subjects: 822

Group type: EXPERIMENTAL
Intervention: Free PSA ratio (FPSAR) <0.10 in RT cohort
Number of subjects: 822
Study: 32926871

Group type: EXPERIMENTAL
Intervention: Smartphone sensor with app
Number of subjects: 320

Group type: COMPARATOR
Intervention: Hospital reference devices
Number of subjects: 320
Study: 32927016

Group type: EXPERIMENTAL
Intervention: 500 mL of orange juice (OJ)
Number of subjects: 0
Study: 32928136

Group type: EXPERIMENTAL
Intervention: Salvage chemoradiation therapy (CRT)
Number of subjects: 0
Study: 32928264

Group type: EXPERIMENTAL
Intervention: Endocrine therapy and palbociclib
Number of subjects: 103
Study: 32928498

Group type: EXPERIMENTAL
Intervention: Targeted ultrasound following mammography for SDDs
Number of subjects: 130

Group type: COMPARATOR
Intervention: Mammography alone for SDDs
Number of subjects: 130
Study: 32928500

Group type: EXPERIMENTAL
Intervention: Antipsychotic-naïve patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia diagnosis
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both patients and healthy control subjects
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 56
Study: 32928517

Group type: EXPERIMENTAL
Intervention: Epinephrine administration before ICU admission
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Fluid resuscitation
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Lactate concentration at ICU admission
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Mortality rate
Number of subjects: 339
Study: 32928701

Group type: EXPERIMENTAL
Intervention: Alternate OGTT measures (time to peak glucose >30 minutes)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 1-hour glucose (1hG) ≥155 mg/dL
Number of subjects: 52

Group type: COMPARATOR
Intervention: Traditional OGTT criteria for prediabetes
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Alternate OGTT measures (time to peak glucose and 1hG)
Number of subjects: 52
Study: 32928795

Group type: EXPERIMENTAL
Intervention: Pomalidomide, low-dose dexamethasone (LoDEX), and daratumumab
Number of subjects: 0
Study: 32928796

Group type: EXPERIMENTAL
Intervention: Flumatinib 600 mg once daily
Number of subjects: 394

Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 394
Study: 32928858

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) treatment initiated prior to 20 weeks gestation, cessation of TDF 1 month after delivery.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Tenofovir concentrations in maternal and cord plasma measured in 10-15 women with detectable HBV DNA at delivery.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Infant HBsAg status determined at 2 months of age.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Monitoring of adverse events including risk of flare and adherence based on pill count and questionnaire.
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Infants receive HBV vaccinations at birth, 2, 4, and 6 months and hepatitis B immunoglobulin at birth if the mother is hepatitis B e antigen positive.
Number of subjects: 170
Study: 32928999

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Microsurgery
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Embolisation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Embolisation + SRS
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Partial occlusion
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Different management modalities
Number of subjects: 61
Study: 32929049

Group type: EXPERIMENTAL
Intervention: RivoCel (donor-derived T cells genetically modified with a suicide gene for iCaspase9 and truncated CD19 for cell tracking)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: CD19-specific CAR T cells
Number of subjects: 1
Study: 32929265

Group type: EXPERIMENTAL
Intervention: iPSC-derived mesenchymal stromal cells (MSCs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32929393

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32929477

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Type 1 Diabetes (T1D) with HbA1c > 8.5%
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control (without T1D)
Number of subjects: 123
Study: 32929483

Group type: EXPERIMENTAL
Intervention: Frail patients (CAF score ≥11)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Increased CAF score
Number of subjects: 604

Group type: COMPARATOR
Intervention: Non-frail patients (CAF score <11)
Number of subjects: 604
Study: 32929488

Group type: EXPERIMENTAL
Intervention: Flotetuzumab at RP2D of 500 ng/kg per day
Number of subjects: 88
Study: 32929659

Group type: EXPERIMENTAL
Intervention: PREDICT app (after phase)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Standard care (before phase)
Number of subjects: 183
Study: 32930023

Group type: EXPERIMENTAL
Intervention: Current snus users
Number of subjects: 914

Group type: COMPARATOR
Intervention: Noncurrent snus users
Number of subjects: 914
Study: 32930325

Group type: EXPERIMENTAL
Intervention: CHO intake
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: FAT intake
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: CHO/FAT ratio
Number of subjects: 4209

Group type: EXPERIMENTAL
Intervention: CPT1A mRNA expression
Number of subjects: 4209
Study: 32930463

Group type: EXPERIMENTAL
Intervention: Patients with idiopathic gastroparesis over 48 weeks
Number of subjects: 138
Study: 32930807

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 20
Study: 32930938

Group type: EXPERIMENTAL
Intervention: Lean-Facilitation intervention (LFI)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Matched comparison clinics (Control)
Number of subjects: 68
Study: 32930969

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32930988

Group type: EXPERIMENTAL
Intervention: DPA gait assessment using a tri-axial accelerometer for 48 hours
Number of subjects: 63
Study: 32931190

Group type: EXPERIMENTAL
Intervention: State-Trait Anxiety Inventory State ≥ 40 (moderate to severe anxiety)
Number of subjects: 391
Study: 32931306

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 3655

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 3655
Study: 32931398

Group type: EXPERIMENTAL
Intervention: Ibrutinib at 420 mg/d
Number of subjects: 63
Study: 32931555

Group type: EXPERIMENTAL
Intervention: Increased arm size
Number of subjects: 647

Group type: COMPARATOR
Intervention: No increased arm size
Number of subjects: 647
Study: 32931556

Group type: EXPERIMENTAL
Intervention: Week 6 faecal calprotectin <250 mg/kg
Number of subjects: 677

Group type: COMPARATOR
Intervention: Other Week 6 clinical assessments (clinical remission or clinical response)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Other biomarkers (CRP <5 or drug level)
Number of subjects: 677
Study: 32931710

Group type: EXPERIMENTAL
Intervention: Risk medication usage
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) usage
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Incidence of upper gastrointestinal bleeding
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 543
Study: 32931958

Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Clopidogrel alone
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Dual-antiplatelet therapy
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants
Number of subjects: 602

Group type: COMPARATOR
Intervention: Clinician nonadherence to guidelines
Number of subjects: 602
Study: 32933420

Group type: EXPERIMENTAL
Intervention: Admission-to-groin-puncture (ATG) delay
Number of subjects: 2386

Group type: EXPERIMENTAL
Intervention: Symptom-onset-to-admission delay
Number of subjects: 2386

Group type: EXPERIMENTAL
Intervention: Adjusted ATG delay
Number of subjects: 2386
Study: 32933511

Group type: EXPERIMENTAL
Intervention: HOM group (ICCH enrollment)
Number of subjects: 2524

Group type: COMPARATOR
Intervention: CON group (usual care)
Number of subjects: 2524
Study: 32933863

Group type: EXPERIMENTAL
Intervention: Initial decreases in depressive symptoms over the first two years (5.2% of participants)
Number of subjects: 2308

Group type: COMPARATOR
Intervention: Stable low to average levels of depressive symptoms (87.0% of participants)
Number of subjects: 2308
Study: 32933874

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) in combination with a new-generation drug-eluting stent (DES)
Number of subjects: 100
Study: 32933920

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 32933956

Group type: EXPERIMENTAL
Intervention: Measurement of brain tissue oxygenation using invasive techniques
Number of subjects: 0
Study: 32934619

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:00.000 adrenaline
Number of subjects: 95

Group type: COMPARATOR
Intervention: 3% prilocaine with 3% felypressin (0.03 I.U. per ml)
Number of subjects: 95